QQQ   354.92 (-1.75%)
AAPL   172.40 (-0.78%)
MSFT   313.39 (-2.61%)
META   300.94 (-1.92%)
GOOGL   132.43 (-1.30%)
AMZN   124.72 (-3.66%)
TSLA   246.53 (-2.02%)
NVDA   435.17 (-2.82%)
NIO   8.61 (-2.05%)
BABA   84.57 (-2.27%)
AMD   100.08 (-3.09%)
T   14.79 (+0.82%)
F   12.07 (-1.95%)
MU   67.83 (-0.19%)
CGC   0.68 (-6.82%)
GE   107.77 (-0.94%)
DIS   79.54 (-2.61%)
AMC   7.86 (-3.56%)
PFE   33.90 (-0.12%)
PYPL   57.30 (-2.15%)
NFLX   376.75 (-0.94%)
QQQ   354.92 (-1.75%)
AAPL   172.40 (-0.78%)
MSFT   313.39 (-2.61%)
META   300.94 (-1.92%)
GOOGL   132.43 (-1.30%)
AMZN   124.72 (-3.66%)
TSLA   246.53 (-2.02%)
NVDA   435.17 (-2.82%)
NIO   8.61 (-2.05%)
BABA   84.57 (-2.27%)
AMD   100.08 (-3.09%)
T   14.79 (+0.82%)
F   12.07 (-1.95%)
MU   67.83 (-0.19%)
CGC   0.68 (-6.82%)
GE   107.77 (-0.94%)
DIS   79.54 (-2.61%)
AMC   7.86 (-3.56%)
PFE   33.90 (-0.12%)
PYPL   57.30 (-2.15%)
NFLX   376.75 (-0.94%)
QQQ   354.92 (-1.75%)
AAPL   172.40 (-0.78%)
MSFT   313.39 (-2.61%)
META   300.94 (-1.92%)
GOOGL   132.43 (-1.30%)
AMZN   124.72 (-3.66%)
TSLA   246.53 (-2.02%)
NVDA   435.17 (-2.82%)
NIO   8.61 (-2.05%)
BABA   84.57 (-2.27%)
AMD   100.08 (-3.09%)
T   14.79 (+0.82%)
F   12.07 (-1.95%)
MU   67.83 (-0.19%)
CGC   0.68 (-6.82%)
GE   107.77 (-0.94%)
DIS   79.54 (-2.61%)
AMC   7.86 (-3.56%)
PFE   33.90 (-0.12%)
PYPL   57.30 (-2.15%)
NFLX   376.75 (-0.94%)
QQQ   354.92 (-1.75%)
AAPL   172.40 (-0.78%)
MSFT   313.39 (-2.61%)
META   300.94 (-1.92%)
GOOGL   132.43 (-1.30%)
AMZN   124.72 (-3.66%)
TSLA   246.53 (-2.02%)
NVDA   435.17 (-2.82%)
NIO   8.61 (-2.05%)
BABA   84.57 (-2.27%)
AMD   100.08 (-3.09%)
T   14.79 (+0.82%)
F   12.07 (-1.95%)
MU   67.83 (-0.19%)
CGC   0.68 (-6.82%)
GE   107.77 (-0.94%)
DIS   79.54 (-2.61%)
AMC   7.86 (-3.56%)
PFE   33.90 (-0.12%)
PYPL   57.30 (-2.15%)
NFLX   376.75 (-0.94%)
NASDAQ:ISPC

iSpecimen (ISPC) Competitors

$0.58
-0.03 (-4.91%)
(As of 10/3/2023 ET)
Compare
Today's Range
$0.52
▼
$0.61
50-Day Range
$0.58
▼
$1.69
52-Week Range
$0.52
▼
$2.05
Volume
18,716 shs
Average Volume
27,174 shs
Market Capitalization
$5.27 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.00
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

ISPC vs. BIAF, AIKI, ADXN, ATXI, NURO, AVGR, AEMD, SILO, FRTX, and VVOS

Should you be buying iSpecimen stock or one of its competitors? The main competitors of iSpecimen include bioAffinity Technologies (BIAF), AIkido Pharma (AIKI), Addex Therapeutics (ADXN), Avenue Therapeutics (ATXI), NeuroMetrix (NURO), Avinger (AVGR), Aethlon Medical (AEMD), Silo Pharma (SILO), Fresh Tracks Therapeutics (FRTX), and Vivos Therapeutics (VVOS). These companies are all part of the "medical" sector.

iSpecimen vs.

iSpecimen (NASDAQ:ISPC) and bioAffinity Technologies (NASDAQ:BIAF) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, dividends, valuation, risk, community ranking, profitability, earnings and analyst recommendations.

iSpecimen has a net margin of -110.39% compared to bioAffinity Technologies' net margin of -39,277.73%. iSpecimen's return on equity of -59.17% beat bioAffinity Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
iSpecimen-110.39% -59.17% -48.54%
bioAffinity Technologies -39,277.73%-92.37%-83.91%

In the previous week, iSpecimen and iSpecimen both had 3 articles in the media. iSpecimen's average media sentiment score of 0.30 equaled bioAffinity Technologies'average media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
iSpecimen
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
bioAffinity Technologies
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

4.6% of iSpecimen shares are owned by institutional investors. Comparatively, 1.1% of bioAffinity Technologies shares are owned by institutional investors. 32.7% of iSpecimen shares are owned by insiders. Comparatively, 44.3% of bioAffinity Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

iSpecimen currently has a consensus target price of $11.00, suggesting a potential upside of 1,900.00%. Given iSpecimen's higher probable upside, equities research analysts plainly believe iSpecimen is more favorable than bioAffinity Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
iSpecimen
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
bioAffinity Technologies
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

iSpecimen received 3 more outperform votes than bioAffinity Technologies when rated by MarketBeat users.

CompanyUnderperformOutperform
iSpecimenOutperform Votes
3
75.00%
Underperform Votes
1
25.00%
bioAffinity TechnologiesN/AN/A

bioAffinity Technologies has lower revenue, but higher earnings than iSpecimen.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
iSpecimen$10.40M0.53-$10.25M-$1.25-0.49
bioAffinity TechnologiesN/AN/A-$8.15MN/AN/A

Summary

iSpecimen beats bioAffinity Technologies on 7 of the 9 factors compared between the two stocks.


Get iSpecimen News Delivered to You Automatically

Sign up to receive the latest news and ratings for ISPC and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ISPC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ISPC vs. The Competition

Export to Excel
MetriciSpecimenCommercial physical research IndustryMedical SectorNASDAQ Exchange
Market Cap$5.53M$4.02B$4.42B$6.20B
Dividend YieldN/A1.38%5.86%7.83%
P/E Ratio-0.4918.85121.3111.96
Price / Sales0.5369.002,883.2766.39
Price / CashN/A28.6321.3922.77
Price / Book0.262.933.824.56
Net Income-$10.25M$87.05M$121.29M$181.66M
7 Day Performance-0.02%0.29%-2.00%-1.97%
1 Month Performance-14.22%-8.30%-7.91%-9.14%
1 Year Performance-64.95%-28.49%7.16%1.95%

iSpecimen Competitors List

Export to Excel
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BIAF
bioAffinity Technologies
0 of 5 stars		$1.09
+10.1%		N/A-51.2%$10.19M$24,156.000.0014Short Interest ↑
Gap Down
AIKI
AIkido Pharma
0 of 5 stars		$2.35
+1.7%		$16.00
+580.9%		-65.8%$12.89M$10,000.00-0.614Gap Up
ADXN
Addex Therapeutics
1.3987 of 5 stars		$0.37
+5.7%		N/A-55.0%$5.52M$1.51M-0.2824Gap Up
ATXI
Avenue Therapeutics
2.1153 of 5 stars		$0.68
+21.4%		$32.00
+4,605.9%		-93.2%$5.56MN/A-0.612Positive News
Gap Up
NURO
NeuroMetrix
0 of 5 stars		$0.64
flat		N/A-74.6%$5.49M$7.20M-0.9027News Coverage
AVGR
Avinger
2.4235 of 5 stars		$7.61
-15.0%		$24.00
+215.4%		-71.6%$5.48M$8.27M-0.1871Analyst Report
AEMD
Aethlon Medical
0 of 5 stars		$0.22
flat		N/A-60.7%$5.44M$570,000.00-0.4115Analyst Report
Short Interest ↑
News Coverage
SILO
Silo Pharma
1.8823 of 5 stars		$1.82
-1.6%		$10.00
+449.5%		N/A$5.66M$72,102.000.003Gap Down
FRTX
Fresh Tracks Therapeutics
1.4135 of 5 stars		$0.96
+4.3%		$4.00
+316.7%		-45.3%$5.67M$2.60M-0.1913Short Interest ↑
VVOS
Vivos Therapeutics
1.7996 of 5 stars		$0.19
flat		N/A-70.8%$5.71M$16.02M-0.27154News Coverage
Positive News
Gap Up

Related Companies and Tools

Related Companies:
Top 10 Stock Comparisons
This page (NASDAQ:ISPC) was last updated on 10/3/2023 by MarketBeat.com Staff

My Account -